Havens PL et al. – This study evaluated the effect of vitamin D3 (VITD3) on spine bone mineral density (BMD) in young patients with HIV taking tenofovir disoproxil fumarate–containing combination antiretroviral therapy (TDF–cART). The authors concluded that supplementation with VITD3 and multivitamin increased lumbar spine BMD (LSBMD) through 48 weeks independent of the baseline VITD3 values.

Methods

• Randomized, double–blind, placebo–controlled study of HIV patients (16–24 years) on TDF–cART therapy for ≥180 days; participants received VITD3 50,000 IU (n = 109) or placebo (n = 105) and were evaluated every 4 weeks for 48 weeks.

Results

• From baseline to week 48, the VITD3 and placebo groups reported increases in LSBMD by 1.15% and 0.09%, respectively, with no between–group difference.